期刊文献+

新疆80例恶性黑素瘤BRAF基因突变分析 被引量:12

Analysis of BRAF gene mutations in 80 patients with malignant melanoma in Xinjiang Uygur Autonomous Region
原文传递
导出
摘要 目的探讨BRAF基因突变与恶性黑素瘤临床表现的关系。方法PCR及DNA直接测序法对新疆80例恶性黑素瘤及30例正常皮肤石蜡包埋组织BRAF基因11、15外显子进行检测。结果80例恶性黑素瘤19例发生BRAF基因突变,突变率为23.8%(19/80);有17例突变发生于15外显子,突变率为89.5%(17/19),其中V600E突变占BRAF基因15外显子突变的88.2%(15/17);2例突变位于11外显子,突变率10.5%(2/19);30例正常皮肤组织均未发现BRAF基因突变。患者平均发病年龄为57.5岁,年龄在60岁以下患者BRAF基因突变率显著高于60岁以上(r=6.613,P〈0.05)。黏膜、肢端、非肢端突变率分别为:18.2%(4/21),14.7%(5,34),41.7%(10/24),差异具有统计学意义(r=6.167,P〈0.05)。BRAF基因突变与恶性黑素瘤患者性别、民族、有无淋巴结转移无明显相关性(P〉0.05)。结论BRAF基因仍为新疆地区恶性黑素瘤热点突变基因,且以该基因15外显子V600E突变为主。BRAF基因突变与恶性黑素瘤患者发病年龄、发病部位密切相关,而与民族、性别、有无淋巴结转移无相关性。 Objective To assess the relationship between BRAF gene mutations and clinical phenotype of malignant melanoma. Methods Tissue specimens were collected from the lesions of 80 patients with malignant melanoma, and from the normal skin of 30 patients with trauma in the Department of Plastic Surgery or General Surgery, and subjected to paraffin embedding and DNA extraction. PCR was performed to amplify the exon 11 and 15 of BRAF gene followed by DNA sequencing. Chi-square test and Fisher's exact test were carried out to assess the relationship between BRAF gene mutations and clinical phenotypes of malignant melanoma. Results BRAF gene mutations were found in 19 (23.8%) of the 80 malignant melanoma specimens. Among the 19 mutation- positive specimens, 17 (88.2%) carried mutations in exon 15 of BRAF gene with V600E as the most frequent (88.2%, 15/17) mutation type, and 2 (10.5%) carried mutations in exon 11. No mutation was found in any of the normal skin tissue specimens. The average age at onset was 57.5 years in these patients. The frequency of BRAF gene mutation was significantly higher in patients younger than 60 years than in those older than 60 years (37.1% vs. 13.3%, X2= 6.613, P 〈 0.05). A significant difference was observed in the frequency of BRAF gene mutation among tissue specimens of mucosal, acral and non-acral malignant melanoma (18.2% (4/2t) vs. 14.7% (5/34) vs. 41.7% (10/24), X2= 6.167, P 〈 0.05). There was no significant association between BRAF gene mutation and gender, race or lymph node metastasis (all P 〉 0.05). Conclusions BRAF gene is a hot spot for mutations in patients with malignant melanoma in Xinjiang Uygur Autonomous Region, with V6OOE point mutation in exon 15 as the most frequent mutation type. BRAF gene mutations appear to be closely correlated with the age at onset of and lesional sites in, but uncorrelated with gender and race of or lymph node metastasis in, patients with malignant melanoma.
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2013年第1期33-36,共4页 Chinese Journal of Dermatology
基金 新疆维吾尔自治区自然科学基金(2012211A086)
关键词 黑色素瘤 基因 BRAF 突变 新疆 Melanoma Genes, BRAF Mutation XINJIANG
  • 相关文献

参考文献10

  • 1Hodi FS, CKDay SJ, McDermott DF, et al. Improved survival withipilimumab in patients with metastatic melanoma. N Engl J Med,2010,363(8): 711-723.
  • 2Kong Y, Si L, Guo J, et al. Aberrations of KIT, BRAF, NRAS, andPDGFRA in Chinese melanoma patients and their significance:Large, scale analysis of 644 patients. J Clin Oncol, 2011, 29(15): 8568.
  • 3Ellerhorst JA, Greene VR,Ekmekcioglu S,et al. Clinical corre-lates of NRAS and BRAF mutations in primary humanmelanoma. Clin Cancer Res, 2011, 17(2): 229-235.
  • 4张成锋,项蕾红,郭坤,刘银坤,郑志忠.人恶性黑素瘤细胞株A375中色素上皮衍生因子基因的突变[J].中华皮肤科杂志,2008,41(10):680-682. 被引量:1
  • 5Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF genein human cancer. Nature, 2002, 417(6892): 949-954.
  • 6Brose MS, Volpe P,Feldman M, et al. BRAF and RAS mutationsin human lung cancer and melanoma. Cancer Res, 2002, 62(23): 6997-7000.
  • 7Goel VK, Lazar AJ, Wameke CL, et al. Examination of mutationsin BRAF, NRAS, and PTEN in primary cutaneous melanomajInvest Dermatol, 2006, 126(1): 154-160.
  • 8郭芳,康晓静.BRAF、NRAS癌基因与恶性黑素瘤的研究[J].国际皮肤性病学杂志,2012,38(1):48-50. 被引量:3
  • 9朱琰琰,斯璐,迟志宏,崔传亮,盛锡楠,李思明,韩梅,郭军.中国黑色素瘤患者BRAF基因突变分析[J].临床肿瘤学杂志,2009,14(7):585-588. 被引量:17
  • 10Dhomen N,Marais R. BRAF signaling and targeted therapies inmelanoma. Hematol Oncol Clin North Am, 2009, 23 (3): 529-545.

二级参考文献33

  • 1张成锋,项蕾红,张勇,李剑,郑志忠.色素痣和恶性黑素瘤组织及A375细胞中色素上皮衍生因子的表达[J].中华皮肤科杂志,2007,40(4):213-216. 被引量:1
  • 2Tombran-Tink J, Chader GG, Johnson LV. PEDF: a pigment epithelium- derived factor with potent neuronal differentiative activity. Exp Eye Res, 1991, 53(3): 411-414.
  • 3Tombran-Tink J, Pawar H, Swaroop A, et al. Localization of the gene for pigment epitheliumderived factor (PEDF) to chromosome 17p13.1 and expression in cultured human retinoblastoma cells. Genomics, 1994, 19(2): 266-272.
  • 4Slavc I, Rodriguez IR, Mazuruk K, et al. Mutation analysis and loss of heterozygosity of PEDF in central nervous system primitive neuroectodermal tumors. Int J Cancer, 1997, 72(2 ): 277-282.
  • 5Sasaki Y, Naishiro Y, Oshima Y, et al. Identification of pigment epithelium-derived factor as a direct target of the p53 family member genes. Oncogene, 2005, 24(32): 5131-5136.
  • 6Jemal A, Siegel R, Ward E, et al. Cancer statistics, CA Cancer J Clin, 2008,56(2):71-96.
  • 7Giblin AV, Thomas JM. Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg, 2007, 60 (1): 32-40.
  • 8Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature, 2002, 417(6892): 949-954.
  • 9Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res, 2002, 62 (23): 6997-7000.
  • 10Flaherty KT, Hodi FS, Bastian BC. Mutation-driven drug development in melanoma. Curr Opin Oncol, 2010, 22 (3): 178- 183.

共引文献18

同被引文献60

  • 1高天文,孙东杰,李春英,何弘,李青,刘友生,刁庆春,黄高升,郝飞,钟白玉,马福成,柳凤轩,闫小初,刘东梅,刘玉峰,刘荣卿.中国西部两医院1905例皮肤恶性肿瘤回顾分析[J].北京大学学报(医学版),2004,36(5):469-472. 被引量:73
  • 2常建民.少见病理类型的恶性黑素瘤[J].中华皮肤科杂志,2005,38(4):255-258. 被引量:3
  • 3安菊生,吴令英,李宁,李斌,俞高志,刘丽影.生殖系统原发性恶性黑色素瘤42例临床分析[J].中华妇产科杂志,2007,42(5):320-324. 被引量:13
  • 4Ordo nez NG.Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: a review and update [J].Hum Pathol, 2014,45(2): 191-205.
  • 5Lade-Keller J,Riber-Hansen R,Guldberg P, et al. Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker[J]. J Clin Pathol, 2014, 67(6):520-528.
  • 6Margaritescu I,ChiriTa AD. Desmoplastic melanoma- challenges in the diagnosis and management of a rare cutaneous tumor [J]. Rom J Morphol Embryol, 2014, 55(3): 947-952.
  • 7Lade-Keller J,Riber-Hansen R,Guldberg P, et al. Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker[J].J Clin Pathol, 2014, 67(6):520-528.
  • 8Lukanidin E, Sleeman JP. Building the niche: the role of the S100 proteins in metastatic growth [J].Semin Cancer Biol, 2012, 22(3): 216-225.
  • 9Ramos-Vara JA,Frank CB,DuSold D,et al. Immunohistochemical expression of melanocytic antigen PNL2,Melan A,S100,and PGP 9.5 in equine melanocytic neoplasms[J].Vet Pathol,2014,51 (1): 161 - 166.
  • 10Ivan D,Prieto VG.Use of immunohistochemistry in the diagnosis of melanocytic lesions: applications and pitfalls [J].Future Oncol, 2010,6(7): 1163-1175.

引证文献12

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部